In:
International Journal of Cancer, Wiley, Vol. 139, No. 6 ( 2016-09-15), p. 1289-1296
Abstract:
What's new? The recent availability of comprehensive data in Germany has made it possible to study population‐level survival for rare cancers such as acute myeloblastic leukemia (AML). Here, the authors offer the first detailed description of AML survival in the country, providing age‐adjusted and age‐specific 1‐ and 5‐year survival estimates and analyzing survival trends. Comparison between Germany and the United States shows higher probability of 1‐ and 5‐year survival in Germany, especially for younger patients. The results suggest incremental progress in the treatment of AML and a need to further investigate risk factors in the United States, especially regarding access to treatment.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2016
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
